STUDY DESIGN: Posterolateral lumbar spine fusions in New Zealand white rabbits. OBJECTIVE: To evaluate the efficacy of recombinant human growth and differentiation factor-5 (rhGDF-5) lyophilized to a Healos carrier (cross-linked type I collagen with hydroxyapatite coating; DePuy Spine, Inc., Raynham, MA) in inducing fusion. SUMMARY OF BACKGROUND DATA: Bone graft substitutes have become an area of considerable interest. rhGDF-5 is one such product. Limited lumbar preclinical studies have been performed with this product. METHODS: Single-level, intertransverse process fusions were performed in 67 rabbits using iliac crest autograft (n = 13), Healos alone (n = 13), or 0.5, 1.0, or 1.5 mg/cc rhGDF-5 lyophilized to Healos (n = 13 per group). At 8 weeks, the rabbits were euthanized. Fusion masses were assessed. RESULTS: There were 2 animals (3%) lost to complication. Manual palpation revealed fusion rates for autograft of 38% (5/13), Healos alone of 0% (0/13), and each of the Healos/rhGDF-5 groups of 100% (13/13). Histologic analyses were 95% sensitive and 95% specific for confirming fusion. Histologic differences were found among the treatment groups. CONCLUSIONS: In this rabbit fusion model, Healos/rhGDF-5 induced fusion in 100% of the rabbits studied. This rate was significantly higher than the fusion rate induced by autograft (38%). Overall, these results support continued research of Healos/rhGDF-5 as a potential bone graft alternative.
STUDY DESIGN: Posterolateral lumbar spine fusions in New Zealand white rabbits. OBJECTIVE: To evaluate the efficacy of recombinant human growth and differentiation factor-5 (rhGDF-5) lyophilized to a Healos carrier (cross-linked type I collagen with hydroxyapatite coating; DePuy Spine, Inc., Raynham, MA) in inducing fusion. SUMMARY OF BACKGROUND DATA: Bone graft substitutes have become an area of considerable interest. rhGDF-5 is one such product. Limited lumbar preclinical studies have been performed with this product. METHODS: Single-level, intertransverse process fusions were performed in 67 rabbits using iliac crest autograft (n = 13), Healos alone (n = 13), or 0.5, 1.0, or 1.5 mg/cc rhGDF-5 lyophilized to Healos (n = 13 per group). At 8 weeks, the rabbits were euthanized. Fusion masses were assessed. RESULTS: There were 2 animals (3%) lost to complication. Manual palpation revealed fusion rates for autograft of 38% (5/13), Healos alone of 0% (0/13), and each of the Healos/rhGDF-5 groups of 100% (13/13). Histologic analyses were 95% sensitive and 95% specific for confirming fusion. Histologic differences were found among the treatment groups. CONCLUSIONS: In this rabbit fusion model, Healos/rhGDF-5 induced fusion in 100% of the rabbits studied. This rate was significantly higher than the fusion rate induced by autograft (38%). Overall, these results support continued research of Healos/rhGDF-5 as a potential bone graft alternative.
Authors: Anthony J Bella; Guiting Lin; Ching-Shwun Lin; Duane R Hickling; Christopher Morash; Tom F Lue Journal: J Sex Med Date: 2009-03 Impact factor: 3.802
Authors: Zamzuri Zakaria; Che N Z C Seman; Zunariah Buyong; Mohd A Sharifudin; Ahmad H Zulkifly; Kamarul A Khalid Journal: Sultan Qaboos Univ Med J Date: 2016-11-30
Authors: Stefan Stich; Anke Möller; Mario Cabraja; Jan Philipp Krüger; Sylvia Hondke; Michaela Endres; Jochen Ringe; Michael Sittinger Journal: Int J Mol Sci Date: 2018-07-28 Impact factor: 5.923
Authors: Steven J Eppell; Weidong Tong; James McMasters; Yohannes Soenjaya; Anca M Barbu; Alvin Ko; Jonathan Z Baskin Journal: Materials (Basel) Date: 2018-08-29 Impact factor: 3.623